Related Experiment Video
Updated: Dec 21, 2025

Genome-Wide CRISPR Screen for Unveiling Radiosensitive and Radioresistant Genes
Published on: May 23, 2025
CRISPR screen in mechanism and target discovery for cancer immunotherapy
Dan Liu1, Xuan Zhao1, Anqun Tang1
1Jiangsu Center for the Collaboration and Innovation of Cancer Biotherapy, Cancer Institute, Xuzhou Medical University, Xuzhou 221000, Jiangsu, China; Center of Clinical Oncology, Affiliated Hospital of Xuzhou Medical University, Xuzhou Medical University, Xuzhou 221000, Jiangsu, China.
Abstract:
CRISPR/Cas-based genetic perturbation screens have emerged as powerful tools for large-scale identification of new targets for cancer immunotherapy. Various strategies of CRISPR screen have been used for immune-oncology (IO) target discovery. The genomic sequences targeted by CRISPR/Cas system range from coding sequences to non-coding RNA/DNA, including miRNAs, LncRNAs, circRNAs, promoters, and enhancers, which may be potential targets for future pharmacological and therapeutic interventions. Rapid progresses have been witnessed in finding novel targets for enhancing tumor antigen presentation, sensitizing of tumor cells to immune-mediated cytotoxicity, and reinvigorating tumor-specific T cells by using CRISPR technologies. In combination with other strategies, the detailed characteristics of the targets for immunotherapy have been obtained by CRISPR screen. In this review, we present an overview of recent progresses in the development of CRISPR-based screens for IO target identification and discuss the challenges and possible solutions in this rapidly growing field.
Insights
CRISPR screens are revolutionizing cancer immunotherapy by identifying new targets. These powerful tools help discover ways to enhance anti-tumor immune responses and develop novel cancer therapies.
Area of Science:
- Genetics
- Immunology
- Oncology
Background:
- CRISPR/Cas-based genetic screens are advanced tools for identifying cancer immunotherapy targets.
- Various CRISPR screen strategies are employed for immune-oncology (IO) target discovery, including coding and non-coding genomic regions.
Purpose of the Study:
- To review recent advancements in CRISPR-based screens for identifying IO targets.
- To discuss challenges and potential solutions in this rapidly evolving field.
Main Methods:
- CRISPR screens targeting diverse genomic elements (coding sequences, miRNAs, LncRNAs, circRNAs, promoters, enhancers).
- Application of CRISPR technologies to enhance tumor antigen presentation, sensitize tumors to cytotoxicity, and reinvigorate T cells.
- Integration of CRISPR screens with other strategies to characterize immunotherapy targets.
Main Results:
- Identification of novel targets for enhancing anti-tumor immunity.
- Progress in understanding mechanisms to improve immune-mediated tumor cell killing.
- Development of strategies to boost tumor-specific T cell responses.
Conclusions:
- CRISPR screens are pivotal in discovering new cancer immunotherapy targets.
- Continued research and innovation are crucial for overcoming challenges in CRISPR-based IO target identification.
More Related Videos
07:37Performing an In Vitro Genome-Wide CRISPR Knockout Screen in Chimeric Antigen Receptor T Cells
Published on: January 31, 2025
07:01Evaluation of Abnormal Growth-related Genes of Hematopoietic Stem and Progenitor Cells by Combining CRISPR/Cas9 Technology with Cell Counting
Published on: May 2, 2025
Related Concept Videos
CRISPR/Cas9 Genome Editing
Genetic Screens
Forward genetic screens
Forward or “classical” genetic screens involve creating random mutations in an organism’s DNA using radiation, mutagens, or insertion of additional bases, which...
CRISPR
Targeted Cancer Therapies
There are several types of targeted therapies against...
The Antiviral System of Bacteria and Archaea: CRISPR